Trial Profile

A Phase 1, Three-Cohort Study to Evaluate the Effect of Three Single Dose Levels of FT-4101 on Hepatic De Novo Lipogenesis (DNL) in Healthy Adult Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FT 4101 (Primary)
Indications Non-alcoholic steatohepatitis
Focus Adverse reactions; Pharmacodynamics
Sponsors FORMA Therapeutics

Most Recent Events

16 Nov 2019 New trial record
08 Nov 2019 According to a FORMA Therapeutics media release, the company announced the presentation of this study at The Liver Meeting 2019, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, 8th-12th Nov, 2019 in Boston, MA).
08 Nov 2019 Results presented in a FORMA Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com